Paper Details
- Home
- Paper Details
Original Abstract of the Article :
Several antidiabetic agents, including thiazolidinediones and sodium-glucose cotransporter (SGLT) 2 inhibitors, attenuate the symptoms of nonalcoholic steatohepatitis (NASH). However, thiazolidinediones have serious side effects such as fluid retention and increased risk of congestive heart failure....See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1016/j.ejphar.2021.174076
データ提供：米国国立医学図書館（NLM）
Understanding the Impact of SGLT2 Inhibitors on Fluid Retention in Diabetic Mice with NASH
The battle against type 2 diabetes and nonalcoholic steatohepatitis (NASH) continues. This study examines the effects of ipragliflozin, an SGLT2 inhibitor, and pioglitazone, a thiazolidinedione, on fluid retention in type 2 diabetic mice with NASH. The researchers aimed to determine the safety and efficacy of these medications in managing fluid retention, a potential side effect of some antidiabetic drugs.
A Delicate Balance Between Benefits and Risks
While both ipragliflozin and pioglitazone have shown promise in treating diabetes and NASH, this study delves into the nuanced effects of these medications on fluid retention. The researchers found that pioglitazone, despite its potential benefits, can lead to fluid retention in mice, while ipragliflozin alone did not.
Navigating the Desert of Diabetes Treatment
This research is a valuable reminder that the path to managing diabetes and NASH is often a complex one, requiring careful consideration of potential side effects. The findings suggest that ipragliflozin may be a safer option for patients with diabetes and NASH who are prone to fluid retention. It's important to note that this research was conducted in mice, and further studies in humans are needed to confirm these findings.
Dr. Camel's Conclusion
Like a camel navigating the desert landscape, managing diabetes and NASH requires navigating a complex terrain of potential benefits and risks. This research is an important step in understanding the effects of SGLT2 inhibitors and thiazolidinediones on fluid retention, providing valuable insights for physicians and patients alike. As the research continues, we're likely to discover more about the intricate balance between medication efficacy and potential side effects, helping us find the most suitable paths for managing these conditions.
Date :
- Date Completed 2021-05-18
- Date Revised 2021-05-18
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.